Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer

Stenman, U H; Leinonen, Jari; Hakama, Matti; Knekt, Paul; Aromaa, Arpo; Teppo, Lyly

doi:10.1016/s0140-6736(94)90405-7

Cited by 246 publications

(135 citation statements)

References 22 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…It is possible that the positive predictive value could be further improved by determining the free PSA concentration in addition to the total PSA (Lilja et al, 1991;Stenman et al, 1991Stenman et al, , 1994. The detection rate for digital rectal examination among men with PSA below 4.0 ng ml Ð1 was an order of magnitude lower than among men with PSA levels above 4 ng ml Ð1 , which is not very encouraging.…”

Section: Discussionmentioning

confidence: 99%

European randomized study of prostate cancer screening: first-year results of the Finnish trial

et al. 1999

Self Cite

View full text Add to dashboard Cite

Prostate cancer is currently the most common cancer among men after skin cancer in most industrialized countries (Parkin et al, 1997). Because of its poorly understood aetiology, primary prevention is not currently feasible and therefore there is considerable interest in screening as a potential approach to prostate cancer control (Schršder and Boyle, 1993). The only means to establish the effect of screening is to conduct large randomized controlled trials with both mortality and quality of life as end points (Denis et al, 1995). Such studies are ongoing both in Europe and North America (Auvinen et al, 1996). In the absence of empirical results, a debate of the issue continues, which is demonstrated by the fact that so far the number of published reviews on the subject exceeds the number of original reports of randomized trials (as identified from Medline).We report here the first-year results of the Finnish trial, which is part of the European Randomized Study of Screening for Prostate Cancer (ERSPC), a multi-centre randomized trial with participating centres from The Netherlands, Finland, Sweden, Belgium, Italy, Portugal and Spain. The common core protocol includes enrolment at ages 55Ð69 and use of Hybritech Tandem-E PSA assay as the screening test with a cut-off level of 4.0 ng ml Ð1 . The primary end point is prostate cancer mortality, with quality of life and cost-effectiveness as the secondary end points. MATERIALS AND METHODSIn the Finnish trial, the subjects are identified from the central population registry of Finland. Enrolment over 4 years with a total study population of 80 000 men is planned. The screening interval is 4 years and up to three screening rounds are planned. The primary end point is mortality from prostate cancer, which will be reported based on 10 years of follow-up from randomization.The study population of the trial consists of men born in 1929Ð1944 and resident in the metropolitan areas of Helsinki and Tampere. In the first year of the study (1996), 20 398 men born in 1929, 1933, 1937 or 1941 were randomized. The subjects were identified from the Population Registry of Finland. The only exclusion criterion was a previous diagnosis of prostate cancer. Information on prostate cancer was obtained through record linkage with the Finnish Cancer Registry. A total of 90 men were excluded before randomization because of previously diagnosed prostate cancer. Approximately 1% of the population (200 men of the eligible study population) has forbidden the use of their address information for any purposes and they were also excluded from randomization. Each year, 8000 men, i.e. approximately one third of the eligible population, are randomized to the screening arm and the rest to the control arm. Of the 8000 men, men who had died or moved out of the study area between the date of randomization (in early January) and date of invitation, were not invited to participate (n = 388 in 1996). Due to an error, additional 275 men were not invited in 1996. Men in the control group were not contacted, ...

show abstract

Section: Discussionmentioning

confidence: 99%

European randomized study of prostate cancer screening: first-year results of the Finnish trial

et al. 1999

Self Cite

View full text Add to dashboard Cite

show abstract

“…21 Most likely a similar degradation will occur in seminal plasma when these samples are stored. The observed di erence found in seminal plasma PSA concentration, however, is unlikely to be explained by storage, as the handling of samples were identical in the two groups.…”

Section: Discussionmentioning

confidence: 99%

Seminal plasma PSA in spinal cord injured men: a preliminary report

et al. 1998

View full text Add to dashboard Cite

Objective: The aim of the study was to evaluate the impact of spinal cord injury on seminal plasma PSA concentration. Material: Semen obtained from normal controls (n=20) and patients (n=16) with spinal cord injury. Results: The concentration of prostate speci®c antigen in seminal plasma depended on the level of spinal cord injury, with signi®cantly lower concentrations in patients with spinal cord lesions below T7 compared to both normal age-matched controls (P=0.007) and patients with spinal cord injuries at or above T7 (P=0.017). Conclusions:The results add to the previously reported observations of the possible impact of neurogenic stimulation on prostate activity. More studies of neurogenic stimulation in prostate growth and development are warranted to further elucidate the possible impact of neurogenic factors in the development of prostatic diseases.

show abstract

“…Now concerning the stability of PSA-F in serum stored at -20°C, there was no concordance between the results of previous studies. According to Woodrum and York (12), PSA-F was stable for 2 years, other authors (6,14) found that the concentration of PSA-F increased in serum after 2 years of storage, in contrary to others (16) who showed that, after one year of storage, PSA-F was stable in some samples and declined in others, but not at the same rate in all specimens.…”

Section: Discussionmentioning

confidence: 91%

“…Therefore, PSA values should be interpreted with caution when the samples have been stored in such detrimental conditions. Stability of PSA stored at various conditions and length of time has been investigated before but in cases the samples were stored at stable temperatures (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). To our knowledge, there is no previous work pertaining to interrupted power supply (and therefore unstable storage temperatures).…”

Section: Introductionmentioning

confidence: 99%

Stability of total and free prostate specific antigen in serum submitted to intermittent cold storage conditions

Ezzi

El‐Saidi

2009

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer

Cited by 246 publications

References 22 publications

European randomized study of prostate cancer screening: first-year results of the Finnish trial

European randomized study of prostate cancer screening: first-year results of the Finnish trial

Seminal plasma PSA in spinal cord injured men: a preliminary report

Stability of total and free prostate specific antigen in serum submitted to intermittent cold storage conditions

Contact Info

Product

Resources

About